Oncology sales drive AstraZeneca’s Q4 Earnings
AstraZeneca’s published Q4 earnings have shown better than expected results, with new launches and commercial execution delivering full-year sales growth and a very strong final quarter.
Read More
Tag: Q4
AZ books 3 percent sales rise for Q4
Anglo-Swedish drugs giant AstraZeneca has booked a 3 percent rise in fourth-quarter sales to $5.8 billion, after growth in product sales was recorded following a number of years of decline.
Read More
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
